Analysis of differentially expressed genes in ductal carcinoma with DNA microarray

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 6, 2013, Pages 758-766

  Zhang, B H ^a   Liu, J ^a   Zhou, Q X ^a   Zuo, D ^a   Wang, Y ^a  

^a EAST CHINA NORMAL UNIVERSITY   (China)

Author keywords

Differentially expressed genes; Invasive ductal carcinoma; Protein interaction network; Transcriptional regulatory network

Indexed keywords

DNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN FOS;

ARTICLE; BIOGENESIS; BREAST CARCINOMA; CARCINOGENESIS; COMPUTER PROGRAM; CONTROLLED STUDY; DATA BASE; DIFFERENTIALLY EXPRESSED GENE; DNA MICROARRAY; DOWN REGULATION; ENRICHMENT CULTURE; GENE; GENE CONSTRUCT; GENE EXPRESSION; GENE REGULATORY NETWORK; HISTOLOGY; HORMONE RESPONSE; HUMAN; HUMAN CELL; METASTASIS; MICROARRAY ANALYSIS; NEOPLASM; ODONTOLOGY; PROTEIN PROTEIN INTERACTION; SIGNIFICANCE ANALYSIS OF MICROARRAY; TRANSCRIPTION REGULATION;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TRANSCRIPTOME;

EID: 84878537900     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. PERSSON I. Estrogens in the causation of breast, endometrial and ovarian cancers-evidence and hypotheses from epidemiological findings. J Steroid Biochem Mol Biol 2000; 74: 357-364.
2. COLEMAN MP, ESTEVE J, DAMIECKI P, ARSLAN A, RENARD H. Trends in cancer incidence and mortality. IARC Sci Publ 1993: 1-806.
3. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: An overview of the randomised trials. Lancet 2005; 365: 1687-1717.
4. AUTIER P, BONIOL M, LA VECCHIA C, VATTEN L, GAVIN A, HERY C, HEANUE M. Disparities in breast cancer mortality trends between 30 european countries: Retrospective trend analysis of who mortality database. Br Med J 2010; 341: c3620.
5. LIPWORTH L. Epidemiology of breast cancer. Eur J Cancer Prev 1995; 4: 7-30.
6. WIECHMANN L, KUERER HM. THE MOLECULAR JOURNEY FROM DUCTAL CARCINOMA IN Situ to invasive breast cancer. Cancer 2008; 112: 2130-2142.
7. DUPONT WD, PARL FF, HARTMANN WH, BRINTON LA, WINFIELD AC, WORRELL JA, SCHUYLER PA, PLUMMER WD. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 1993; 71: 1258-1265.
8. CARTER CL, CORLE DK, MICOZZI MS, SCHATZKIN A, TAYLOR PR. A prospective study of the development of breast cancer in 16,692 women with benign breast disease. Am J Epidemiol 1988; 128: 467-477.
9. NAGLE RB, BOCKER W, DAVIS JR, HEID HW, KAUFMANN M, LUCAS DO, JARASCH ED. Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. J Histochem Cytochem 1986; 34: 869-881.
10. DE MASCAREL I, MACGROGAN G, MATHOULIN-PELISSIER S, SOUBEYRAN I, PICOT V, COINDRE JM. Breast ductal carcinoma in situ with microinvasion: A definition supported by a long-term study of 1248 serially sectioned ductal carcinomas. Cancer 2002; 94: 2134-2142.
11. YU KD, WU LM, LIU GY, WU J, DI GH, SHEN ZZ, SHAO ZM. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (dcis), dcis with microinvasion, and dcis with invasion component. Ann Surg Oncol 2011; 18: 1342-1348.
12. CHAPPELL SA, WALSH T, WALKER RA, SHAW JA. Loss of heterozygosity at chromosome 6q in preinvasive and early invasive breast carcinomas. Br J Cancer 1997; 75: 1324-1329.
13. EBATA A, SUZUKI T, TAKAGI K, MIKI Y, ONODERA Y, NAKAMURA Y, FUJISHIMA F, ISHIDA K, WATANABE M, TAMAKI K, ISHIDA T, OHUCHI N, SASANO H. Oestrogen-induced genes in ductal carcinoma in situ: their comparison with invasive ductal carcinoma. Endocr Relat Cancer 2012; 19: 485-496.
14. KEY T, APPLEBY P, BARNES I, REEVES G. Endogenous sex hormones and breast cancer in postmenopausal women: Reanalysis of nine prospective studies. J Natl Cancer Inst 2002; 94: 606-616.
15. CAULEY JA, LUCAS FL, KULLER LH, STONE K, BROWNER W, CUMMINGS SR. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of osteoporotic fractures research group. Ann Intern Med 1999; 130: 270-277.
16. KABUTO M, AKIBA S, STEVENS RG, NERIISHI K, LAND CE. A prospective study of estradiol and breast cancer in japanese women. Cancer Epidemiol Biomarkers Prev 2000; 9: 575-579.
17. CHEN DT, NASIR A, CULHANE A, VENKATARAMU C, FULP W, RUBIO R, WANG T, AGRAWAL D, MCCARTHY SM, GRUIDL M, BLOOM G, ANDERSON T, WHITE J, QUACKENBUSH J, YEATMAN T. Proliferative genes dominate malignancy-risk gene signature in histologicallynormal breast tissue. Breast Cancer Res Treat 2010; 119: 335-346.
18. IRIZARRY RA, HOBBS B, COLLIN F, BEAZER-BARCLAY YD, ANTONELLIS KJ, SCHERF U, SPEED TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-264.
19. BOLSTAD BM, IRIZARRY RA, ASTRAND M, SPEED TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003; 19: 185-193.
20. HOCHBERG Y, BENJAMINI Y. More powerful procedures for multiple significance testing. Stat Med 1990; 9: 811-818.
21. HUANG DA W, SHERMAN BT, LEMPICKI RA. Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009; 37: 1-13.
22. WINGENDER E, CHEN X, HEHL R, KARAS H, LIEBICH I, MATYS V, MEINHARDT T, PRUSS M, REUTER I, SCHACHERER F. Transfac: An integrated system for gene expression regulation. Nucleic Acids Res 2000; 28: 316-319.
23. PERI S, NAVARRO JD, AMANCHY R, KRISTIANSEN TZ, JONNALAGADDA CK, SURENDRANATH V, NIRANJAN V, MUTHUSAMY B, GANDHI TK, GRONBORG M, IBARROLA N, DESHPANDE N, SHANKER K, SHIVASHANKAR HN, RASHMI BP, RAMYA MA, ZHAO Z, CHANDRIKA KN, PADMA N, HARSHA HC, YATISH AJ, KAVITHA MP, MENEZES M, CHOUDHURY DR, SURESH S, GHOSH N, SARAVANA R, CHANDRAN S, KRISHNA S, JOY M, ANAND SK, MADAVAN V, JOSEPH A, WONG GW, SCHIEMANN WP, CONSTANTINESCU SN, HUANG L, KHOSRAVI-FAR R, STEEN H, TEWARI M, GHAFFARI S, BLOBE GC, DANG CV, GARCIA JG, PEVSNER J, JENSEN ON, ROEPSTORFF P, DESHPANDE KS, CHINNAIYAN AM, HAMOSH A, CHAKRAVARTI A, PANDEY A. Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res 2003; 13: 2363-2371.
24. PALLA G, DERENYI I, FARKAS I, VICSEK T. Uncovering the overlapping community structure of complex networks in nature and society. Nature 2005; 435: 814-818.
25. ADAMCSEK B, PALLA G, FARKAS IJ, DERENYI I, VICSEK T. Cfinder: Locating cliques and overlapping modules in biological networks. Bioinformatics 2006; 22: 1021-1023.
26. FRASOR J, DANES JM, KOMM B, CHANG KC, LYTTLE CR, KATZENELLENBOGEN BS. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003; 144: 4562-4574.
27. LI X, NOTT SL, HUANG Y, HILF R, BAMBARA RA, QIU X, YAKOVLEV A, WELLE S, MUYAN M. Gene expression profiling reveals that the regulation of estrogen-responsive element-independent genes by 17 betaestradiol- estrogen receptor beta is uncoupled from the induction of phenotypic changes in cell models. J Mol Endocrinol 2008; 40: 211-229.
28. NOTT SL, HUANG Y, LI X, FLUHARTY BR, QIU X, WELSHONS WV, YEH S, MUYAN M. Genomic responses from the estrogen-responsive element-dependent signaling pathway mediated by estrogen receptor alpha are required to elicit cellular alterations. J Biol Chem 2009; 284: 15277-15288.
29. ABDOLLAHI A, SCHWAGER C, KLEEFF J, ESPOSITO I, DOMHAN S, PESCHKE P, HAUSER K, HAHNFELDT P, H LATKY L, DEBUS J, PETERS JM, FRIESS H, FOLKMAN J, HUBER PE. Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci USA 2007; 104: 12890-12895.
30. COOPER TF, MORBY AP, GUNN A, SCHNEIDER D. Effect of random and hub gene disruptions on environmental and mutational robustness in escherichia coli. BMC Genomics 2006; 7: 237.
31. DUAN R, PORTER W, SAFE S. Estrogen-induced c-fos protooncogene expression in mcf-7 human breast cancer cells: Role of estrogen receptor sp1 complex formation. Endocrinology 1998; 139: 1981-1990.
32. DUAN R, XIE W, BURGHARDT RC, SAFE S. Estrogen receptor- mediated activation of the serum response element in mcf-7 cells through mapk-dependent phosphorylation of elk-1. J Biol Chem 2001; 276: 11590-11598.
33. MILDE-LANGOSCH K, RODER H, ANDRITZKY B, ASLAN B, HEMMINGER G, BRINKMANN A, BAMBERGER CM, LONING T, BAMBERGER AM. The role of the ap-1 transcription factors c-fos, fosb, fra-1 and fra-2 in the invasion process of mammary carcinomas. Breast Cancer Res Treat 2004; 86: 139-152.
34. REDMOND KL, CRAWFORD NT, FARMER H, D'COSTA ZC, O'BRIEN GJ, BUCKLEY NE, KENNEDY RD, JOHNSTON PG, HARKIN DP, MULLAN PB. T-box 2 represses ndrg1 through an egr1-dependent mechanism to drive the proliferation of breast cancer cells. Oncogene 2010; 29: 3252-3262.
35. VIVACQUA A, ROMEO E, DE MARCO P, DE FRANCESCO EM, ABONANTE S, MAGGIOLINI M. Gper mediates the egr-1 expression induced by 17beta-estradiol and 4-hydroxitamoxifen in breast and endometrial cancer cells. Breast Cancer Res Treat 2012; 133: 1025-1035.
36. JI J, ZHAO L, BUDHU A, FORGUES M, JIA HL, QIN LX, YE QH, YU J, SHI X, TANG ZY, WANG XW. Let-7g targets collagen type i alpha2 and inhibits cell migration in hepatocellular carcinoma. J Hepatol 2010; 52: 690-697.
37. GANSAUGE S, GANSAUGE F, RAMADANI M, STOBBE H, RAU B, HARADA N, BEGER HG. Overexpression of cyclin d1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 1997; 57: 1634-1637.
38. ISHIHARA H, YOSHIDA T, KAWASAKI Y, KOBAYASHI H, YAMASAKI M, NAKAYAMA S, MIKI E, SHOHMI K, MATSUSHIMA T, TADA S, TORIKOSHI Y, MORITA M, TAMURA S, HINO Y, KAMIYAMA J, SOWA Y, TSUCHIHASHI Y, YAMAGISHI H, SAKAI T. A new cancer diagnostic system based on a cdk profiling technology. Biochim Biophys Acta 2005; 1741: 226-233.
39. PETERS MG, VIDAL MDEL C, GIMENEZ L, MAURO L, ARMANASCO E, CRESTA C, BAL DE KIER JOFFE E, PURICELLI L. Prognostic value of cell cycle regulator molecules in surgically resected stage i and ii breast cancer. Oncol Rep 2004; 12: 1143-1150.
40. SORIA JC, JANG SJ, KHURI FR, HASSAN K, LIU D, HONG WK, MAO L. Overexpression of cyclin b1 in earlystage non-small cell lung cancer and its clinical implication. Cancer Res 2000; 60: 4000-4004.
41. SUTTER T, DOI S, CARNEVALE KA, ARBER N, WEINSTEIN IB. Expression of cyclins d1 and e in human colon adenocarcinomas. J Med 1997; 28: 285-309.
42. TAKANO Y, KATO Y, VAN DIEST PJ, MASUDA M, MITOMI H, OKAYASU I. Cyclin d2 overexpression and lack of p27 correlate positively and cyclin e inversely with a poor prognosis in gastric cancer cases. Am J Pathol 2000; 156: 585-594.
43. VAN DIEST PJ, MICHALIDES RJ, JANNINK L, VAN DER VALK P, PETERSE HL, DE JONG JS, MEIJER CJ, BAAK JP. Cyclin d1 expression in invasive breast cancer. Correlations and prognostic value. Am J Pathol 1997; 150: 705-711.
44. ZEESTRATEN EC, MAAK M, SHIBAYAMA M, SCHUSTER T, NITSCHE U, MATSUSHIMA T, NAKAYAMA S, GOHDA K, FRIESS H, VAN DE VELDE CJ, ISHIHARA H, ROSENBERG R, KUPPEN PJ, JANSSEN KP. Specific activity of cyclindependent kinase i is a new potential predictor of tumour recurrence in stage ii colon cancer. Br J Cancer 2012; 106: 133-140.
45. HORIUCHI D, KUSDRA L, HUSKEY NE, CHANDRIANI S, LENBURG ME, GONZALEZ-ANGULO AM, CREASMAN KJ, BAZAROV AV, SMYTH JW, DAVIS SE, YASWEN P, MILLS GB, ESSERMAN LJ, GOGA A. Myc pathway activation in triple-negative breast cancer is synthetic lethal with cdk inhibition. J Exp Med 2012; 209: 679-696.
46. ARRIOLA E, MARCHIO C, TAN DS, DRURY SC, LAMBROS MB, NATRAJAN R, RODRIGUEZ-PINILLA SM, MACKAY A, TAMBER N, FENWICK K, JONES C, DOWSETT M, ASHWORTH A, REIS-FILHO JS. Genomic analysis of the her2/top2a amplicon in breast cancer and breast cancer cell lines. Lab Invest 2008; 88: 491-503.
47. BAO L, KIMZEY A, SAUTER G, SOWADSKI JM, LU KP, WANG DG. Prevalent overexpression of prolyl isomerase pin1 in human cancers. Am J Pathol 2004; 164: 1727-1737.
48. WULF GM, RYO A, WULF GG, LEE SW, NIU T, PETKOVA V, LU KP. Pin1 is overexpressed in breast cancer and cooperates with ras signaling in increasing the transcriptional activity of c-jun towards cyclin d1. EMBO J 2001; 20: 3459-3472.
49. RUSTIGHI A, TIBERI L, SOLDANO A, NAPOLI M, NUCIFORO P, ROSATO A, KAPLAN F, CAPOBIANCO A, PECE S, DI FIORE PP, DEL SAL G. The prolyl-isomerase pin1 is a notch1 target that enhances notch1 activation in cancer. Nat Cell Biol 2009; 11: 133-142.
50. WULF G, GARG P, LIOU YC, IGLEHART D, LU KP. Modeling breast cancer in vivo and ex vivo reveals an essential role of pin1 in tumorigenesis. EMBO J 2004; 23: 3397-3407.
51. GIRARDINI JE, NAPOLI M, PIAZZA S, RUSTIGHI A, MAROTTA C, RADAELLI E, CAPACI V, JORDAN L, QUINLAN P, THOMPSON A, MANO M, ROSATO A, CROOK T, SCANZIANI E, MEANS AR, LOZANO G, SCHNEIDER C, DEL SAL G. A pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 2011; 20: 79-91.
52. KELLER DM, ZENG X, WANG Y, ZHANG QH, KAPOOR M, SHU H, GOODMAN R, LOZANO G, ZHAO Y, LU H. A DNA damage-induced p53 serine 392 kinase complex contains ck2, hspt16, and ssrp1. Mol Cell 2001; 7: 283-292.
53. DE AMICIS F, GIORDANO F, VIVACQUA A, PELLEGRINO M, PANNO ML, TRAMONTANO D, FUQUA SA, ANDO S. Resveratrol, through nf-y/p53/sin3/hdac1 complex phosphorylation, inhibits estrogen receptor alpha gene expression via p38mapk/ck2 signaling in human breast cancer cells. FASEB J 2011; 25: 3695-3707.